IAS 2019: WHO recommends dolutegravir as preferred HIV treatment option in all populations
Based on new evidence assessing benefits and risks, the WHO recommends the use of the HIV drug dolutegravir (DTG) as the preferred first-line and second-line treatment for all populations, including pregnant women and those of childbearing potential.
Initial studies had highlighted a possible link between DTG and neural tube defects (birth defects of the brain and spinal cord that cause conditions such as spina bifida) in infants born to women using the drug at the time of conception. This potential safety concern was reported in May 2018 from a study in Botswana that found 4 cases of neural tube defects out of 426 women who became pregnant while taking DTG. Based on these preliminary findings, many countries advised pregnant women and women of childbearing potential to take efavirenz (EFV) instead.
New data from two large clinical trials comparing the efficacy and safety of DTG and EFV in Africa have now expanded the evidence base. The risks of neural tube defects are significantly lower than what the initial studies may have suggested. DTG is a drug that is more effective, easier to take and has fewer side effects than alternative drugs that are currently used. DTG also has a high genetic barrier to developing drug resistance, which is important given the rising trend of resistance to EFV and nevirapine-based regimens. In 2019, 12 out of 18 countries surveyed by WHO reported pre-treatment drug resistance levels exceeding the recommended threshold of 10%.
WHO press release: https://www.who.int/news-room/detail/22-07-2019-who-recommends-dolutegravir-as-preferred-hiv-treatment-option-in-all-populations
WHO Guideines 2019: https://apps.who.int/iris/bitstream/handle/10665/325892/WHO-CDS-HIV-19.15-eng.pdf
Articles
Edctp Fellow Awarded Wellcome Leap Grant For Tb Research
EDCTP Career Development Fellow Dr Virginie Rozot, a research officer at the South African Tuberculosis Vaccine Initiative (SATVI), has been awarded a multi‑year contract under Wellcome Leap’s Delta Tissue (∆T) programme. Her research will investigate how the human immune system responds to Mycobacterium tuberculosis in the thoracic lymph nodes, and why these responses sometimes fail, allowing the bacteria to spread to other organs. The findings are expected to inform future TB vaccine design and vaccination strategies.
Applications Are Now Open For The Edctp Prizes 2027
Global Health EDCTP3 is now inviting applications for the EDCTP Prizes 2027, recognising outstanding individuals and research teams from Africa and Europe for their achievements in global health research and innovation.
The 2027 edition will award four prize categories, highlighting excellence in scientific leadership, collaborative team research, and gender-balanced scientific contributions. Prize winners will be announced at the EDCTP Forum 2027 in Madrid, Spain. Submissions are open until 2 September 2026.
Edctp Forum 2027: Calls For Abstracts, Scientific Symposia And Workshops Now Open
Global Health EDCTP3 has opened the calls for abstracts, scientific symposia and workshops for the EDCTP Forum 2027, one of the leading global health research events focused on infectious diseases in sub-Saharan Africa. The deadline for submissions is 2 September 2026 at 17:00 (Brussels time).
Under the theme ‘Innovating together for resilient global health', the 13th edition of the EDCTP Forum, taking place from 5-9 April 2027 in Madrid, Spain, will offer researchers, policymakers, funders and implementers the opportunity to showcase their work at a flagship global health event.
The Forum offers a unique platform to share research findings, build partnerships and help shape discussions on global health priorities. Currently, submissions for abstracts, scientific symposia and workshops are open.